CCM
CTSO icon

Cadence Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Cadence Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-12,214
Closed -$61K – 432
2019
Q3 		$61K Buy
+12,214
New +$71.1K 0.01% 412

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Cadence Capital Management's CTSO Position: Q4 2019 in Review

Cadence Capital Management sold out of Cytosorbents Corp (CTSO) in Q4 2019, closing a stake of 12,214 shares — an estimated $61K sold.

Cadence Capital Management first reported a position in CTSO in Q3 2019 and held it in 1 quarter. The position peaked at $61K in Q3 2019. 72 funds tracked by Wall St. Rank hold CTSO as of Q4 2019.

  • Cadence Capital Management reported no remaining Cytosorbents Corp position as of Q4 2019 after selling out during the quarter.
  • Cadence Capital Management sold 12,214 Cytosorbents Corp shares in Q4 2019, an estimated $61K.
  • Cadence Capital Management first reported a position in Cytosorbents Corp in Q3 2019 and held it in 1 quarter.
  • Cadence Capital Management's Cytosorbents Corp position peaked at $61K in Q3 2019.
  • 72 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2019.

Based on Cadence Capital Management's 13F filing for Q4 2019, filed 3 Feb 2020.